Iovance Biotherapeutics financials
$14.45+31.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | $0.00 | $0.00 | — | — | — | — |
| Gross profit | $90.3M | $70.8M | $156.0K | $0.00 | $0.00 | — | — | — | — |
| Gross margin | 34.3% | 43.2% | 13.1% | — | — | — | — | — | — |
| Operating income | -$403.4M | -$395.3M | -$460.6M | -$398.9M | -$342.7M | -$261.9M | -$206.9M | -$128.3M | -$92.9M |
| Net income | -$391.0M | -$372.2M | -$444.0M | -$395.9M | -$342.3M | -$259.6M | -$197.6M | -$123.6M | -$92.1M |
| Net margin | −148.4% | −226.8% | −37345.4% | — | — | — | — | — | — |
| Diluted EPS | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | $-1.27 | $-1.41 |
| EBITDA | -$362.3M | -$357.6M | -$439.1M | -$389.6M | -$328.7M | -$253.2M | -$198.7M | -$127.3M | -$91.9M |
| Operating cash flow | -$302.4M | -$353.0M | -$361.8M | -$292.8M | -$227.9M | -$205.1M | -$158.9M | -$101.2M | -$78.7M |
| Free cash flow | -$336.2M | -$364.0M | -$384.1M | -$313.2M | -$265.5M | -$251.9M | -$165.8M | -$102.4M | -$79.7M |
| Diluted shares | 357.3M | 289.9M | 235.1M | 159.3M | 153.4M | 138.3M | 124.3M | 97.3M | 65.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $163.1M | $115.7M | $114.9M | $231.7M | $78.2M | $67.3M |
| Short-term investments | $133.9M | $208.1M | $165.0M | $240.1M | $426.2M | $562.1M |
| Total debt | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $0.00 |
| Total assets | $913.2M | $910.4M | $780.4M | $664.0M | $777.3M | $768.5M |
| Total liabilities | $214.6M | $200.0M | $195.7M | $164.3M | $155.7M | $112.0M |
| Shareholders' equity | $698.6M | $710.4M | $584.6M | $499.6M | $621.7M | $656.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology